FDA actions in brief, January 2009 (Banzel, tapentadol, synthetic conjugated estrogens-A, Ranexa)
Recent FDA approvals (through January 2009) related to Banzel, tapentadol, synthetic conjugated estrogens-A, and Ranexa
Rufinamide (Banzel, Eisai) was approved for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children aged ≥4 years and adults.
Tapentadol immediate-release tablets (Johnson & Johnson) were approved for the relief of moderate-to-severe acute pain in adults aged ≥18 years.
Synthetic conjugated estrogens-A (SCE-A) 0.625 mg/g vaginal cream (Duramed) was approved for the treatment of moderate-to-severe vaginal dryness and pain with intercourse.
Ranolazine (Ranexa, CV Therapeutics) was approved for the first-line treatment of chronic angina.
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More
